John G Ullman & Associates Inc. Acquires New Position in Hologic, Inc. (HOLX)

John G Ullman & Associates Inc. acquired a new position in Hologic, Inc. (NASDAQ:HOLX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 6,200 shares of the medical equipment provider’s stock, valued at approximately $254,000.

Several other institutional investors also recently modified their holdings of HOLX. Reilly Financial Advisors LLC increased its position in shares of Hologic by 3.7% during the third quarter. Reilly Financial Advisors LLC now owns 39,430 shares of the medical equipment provider’s stock valued at $1,616,000 after acquiring an additional 1,390 shares during the last quarter. Sentry Investment Management LLC increased its position in shares of Hologic by 8.3% during the second quarter. Sentry Investment Management LLC now owns 18,271 shares of the medical equipment provider’s stock valued at $726,000 after acquiring an additional 1,394 shares during the last quarter. CIBC Asset Management Inc increased its position in shares of Hologic by 4.1% during the second quarter. CIBC Asset Management Inc now owns 38,603 shares of the medical equipment provider’s stock valued at $1,534,000 after acquiring an additional 1,504 shares during the last quarter. Majedie Asset Management Ltd grew its holdings in Hologic by 1.5% during the third quarter. Majedie Asset Management Ltd now owns 105,302 shares of the medical equipment provider’s stock valued at $4,315,000 after purchasing an additional 1,589 shares during the period. Finally, State Board of Administration of Florida Retirement System grew its holdings in Hologic by 0.4% during the third quarter. State Board of Administration of Florida Retirement System now owns 412,544 shares of the medical equipment provider’s stock valued at $16,906,000 after purchasing an additional 1,600 shares during the period. 98.74% of the stock is owned by hedge funds and other institutional investors.

Shares of HOLX stock opened at $39.99 on Tuesday. The company has a current ratio of 1.29, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12. Hologic, Inc. has a 52-week low of $35.10 and a 52-week high of $45.09. The firm has a market capitalization of $10.92 billion, a P/E ratio of 19.70, a price-to-earnings-growth ratio of 1.83 and a beta of 0.65.

In related news, insider Benjamin Jordan Cohn sold 3,437 shares of the stock in a transaction on Wednesday, September 19th. The stock was sold at an average price of $41.50, for a total value of $142,635.50. Following the sale, the insider now owns 16,520 shares in the company, valued at $685,580. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Sally Crawford sold 13,257 shares of the stock in a transaction on Monday, September 17th. The stock was sold at an average price of $39.54, for a total value of $524,181.78. Following the completion of the sale, the director now owns 167,701 shares in the company, valued at approximately $6,630,897.54. The disclosure for this sale can be found here. Insiders sold 47,661 shares of company stock worth $1,927,174 in the last quarter. 0.88% of the stock is currently owned by company insiders.

Several brokerages have weighed in on HOLX. BidaskClub lowered Hologic from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 25th. Morgan Stanley cut their price target on Hologic from $47.00 to $44.00 and set an “equal weight” rating for the company in a report on Thursday, October 11th. Zacks Investment Research lowered Hologic from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. UBS Group initiated coverage on Hologic in a report on Tuesday, October 9th. They issued a “neutral” rating and a $44.00 price target for the company. Finally, Canaccord Genuity raised their price target on Hologic from $40.00 to $41.00 and gave the stock a “hold” rating in a report on Thursday, September 27th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $44.47.

COPYRIGHT VIOLATION WARNING: “John G Ullman & Associates Inc. Acquires New Position in Hologic, Inc. (HOLX)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/06/john-g-ullman-associates-inc-acquires-new-position-in-hologic-inc-holx.html.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Recommended Story: Bond

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply